US Capitol Capsule: Will next 4 years mean struggling, juggling, haggling for biopharma?
This article was originally published in Scrip
With President Barack Obama officially taking the oath of office at the White House on 20 January – with the ceremonial swearing in on 21 January on Capitol Hill – came not only the beginning of his second term, but the continuation of many difficult problems and some expected and likely unforeseen challenges ahead, along with the start of the clock ticking away on his dwindling power in a toxic Washington atmosphere.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.